Elbasvir/grazoprevir,
does it really help with Virologic cure at 12 weeks after treatment for chronic hepatitis C genotypes 1 and 4?
research showsElbasvir/grazoprevir is rated A because it produces high SVR12 cure rates after 12 weeks in chronic hepatitis C genotypes 1 and 4. In C-EDGE Treatment-Naive, 299 of 316 participants overall, 129 of 131 with genotype 1b, and all 18 with genotype 4 achieved SVR12. In C-EDGE Head-to-Head, 128 of 129 participants achieved SVR12 compared with 114 of 126 receiving sofosbuvir, peginterferon, and ribavirin, and C-SURFER achieved 115 of 116 in severe chronic kidney disease. SVR12 is a hard cure endpoint, and manufacturer-concentration rule ②-b does not apply to prescription-drug randomized trials with hard endpoints. Strong genotype 1 evidence and specificity to the fixed-dose combination support A, while the 18-person genotype 4 sample, genotype 1a dependence on NS5A resistance, and partial use of historical comparison place it in the lower-middle A range with 86 points.
ads claimPromotion can simplify a 12-week cure into the same one-tablet course for every person with hepatitis C. Actual prescribing depends on genotype and subtype, baseline resistance, compensated versus decompensated liver status, prior treatment, and concomitant medicines. Cure does not create immunity to reinfection or erase established cirrhosis.
Useful facts when choosing a product
- Zepatier is a prescription fixed-dose tablet containing elbasvir 50 mg and grazoprevir 100 mg, generally taken once daily with or without food.
- A 12-week course applies to eligible genotype 1 or 4 patients, but baseline NS5A resistance-associated substitutions in genotype 1a, prior treatment, and the regional label may require ribavirin, a different duration, or another regimen.
- It is not used in decompensated cirrhosis or moderate-to-severe hepatic impairment; hepatitis B markers and liver function are checked before treatment, with monitoring for late ALT elevations.
- Strong CYP3A inducers and certain OATP1B1/3 inhibitors may be contraindicated or not recommended, so all prescription drugs, nonprescription medicines, and supplements require interaction review.
What the research actually shows
The 2015 C-EDGE Treatment-Naive trial by Zeuzem and colleagues randomized 421 participants with genotypes 1, 4, or 6 in a 3:1 ratio to immediate 12-week treatment or deferred-treatment placebo. Among 316 immediately treated participants, 299 achieved SVR12: 92% with genotype 1a, 99% with genotype 1b, and 18 of 18 with genotype 4. The 2016 C-EDGE Head-to-Head trial by Sperl and colleagues randomized 257 participants with genotype 1 or 4 to elbasvir/grazoprevir or sofosbuvir, peginterferon, and ribavirin, reporting 99.2% versus 90.5% SVR12. The 2015 C-SURFER trial by Roth and colleagues achieved SVR12 in 115 of 116 participants with genotype 1 and stage 4 or 5 chronic kidney disease. All pivotal studies were Merck-sponsored, and patients with pre-existing cirrhosis still require liver-cancer surveillance after cure.
Why this is classified as A (86)
SVR12 in 299 of 316 in C-EDGE Treatment-Naive, 128 of 129 in Head-to-Head, and 115 of 116 in C-SURFER shows a very large and repeated 12-week cure effect centered on genotype 1. SVR12 is a hard cure endpoint, and manufacturer-concentration rule ②-b does not apply to prescription-drug randomized trials with hard endpoints, so the strong genotype 1 and 4 evidence specific to this fixed-dose combination supports A. The 18-of-18 genotype 4 sample, genotype 1a dependence on NS5A resistance, and partial historical comparison place it in the lower-middle A range with 86 points.
Counterpoint. Patients can be reinfected after SVR12, and those who had cirrhosis do not stop hepatocellular-carcinoma surveillance. Cure means virologic cure, not the immediate elimination of every long-term liver-disease risk.
Rejudgment record. Cross-check applied — Rated the genotype 1 and 4 evidence specific to this fixed-dose combination as A because C-EDGE and C-SURFER repeatedly achieved hard-endpoint SVR12 cure rates around 95% to 99% and manufacturer-concentration rule ②-b does not apply to prescription-drug randomized trials with hard endpoints, while the 18-of-18 genotype 4 sample, genotype 1a dependence on NS5A resistance, and partial historical comparison place the score in the lower-middle A range at 86
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| SVR12 cure after 12 weeks for chronic hepatitis C genotype 1 | A | Several phase 3 studies replicated hard-endpoint cure rates around 95% to 99%, providing strong genotype 1 evidence. |
| SVR12 cure after 12 weeks for chronic hepatitis C genotype 4 | A | All 18 participants with genotype 4 were cured in C-EDGE, although the direct sample remains small. |
| SVR12 cure after 12 weeks for genotype 1 with stage 4 or 5 chronic kidney disease | A | C-SURFER achieved the hard cure endpoint of SVR12 in 115 of 116 participants, although efficacy was analyzed against a historical control. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Zeuzem S et al. 2015 C-EDGE Treatment-Naive | Multicenter randomized double-blind placebo deferred-treatment phase 3 trial | 105 | Sponsored by Merck & Co. | SVR12 after 12 weeks of treatment | SVR12 was achieved by 299 of 316 overall, 92% with genotype 1a, 99% with genotype 1b, and all 18 with genotype 4. | Pivotal genotype 1 and 4 cure evidence |
| Sperl J et al. 2016 C-EDGE Head-to-Head | Multicenter randomized open-label active-controlled phase 3 trial | 255 | Sponsored by Merck Sharp & Dohme | SVR12 | SVR12 was 128 of 129 (99.2%) with elbasvir/grazoprevir versus 114 of 126 (90.5%) with sofosbuvir, peginterferon, and ribavirin. | Direct active-comparator confirmation |
| Roth D et al. 2015 C-SURFER | Randomized placebo deferred-treatment safety comparison with historical-control phase 3 efficacy analysis | 116 | Sponsored by Merck Sharp & Dohme | SVR12 in genotype 1 with stage 4 or 5 chronic kidney disease | SVR12 was achieved by 115 of 116 participants (99%), with one virologic relapse. | Replication in severe chronic kidney disease |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-24).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Elbasvir/grazoprevir x SVR12 cure after 12 weeks for hepatitis C genotypes 1 and 4 — Evidence Grade A·86. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/liver/elbasvir-grazoprevir-genotype-1-4-hepatitis-c-svr12/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.